US regulators have issued a green light for Teva’s ProAir RespiClick (albuterol sulfate inhalation powder), the first breath-actuated dry-powder inhaler cleared for acute asthma symptoms.

The US Food and Drug Administration has approved the short-acting beta-agonist inhaler for treating or preventing bronchospasm in patients aged 12 years and above with reversible obstructive airway disease, and for the prevention of exercise-induced bronchospasm.

Approval was based on data from eight clinical trials showing that ProAir RespiClick was safe and effective, with a side-effects profile consistent with that seen in earlier albuterol inhalers. 

A US launch is expected during the second quarter of 2015.